The investment will be funded through a combination of Haleon’s existing cash resources and new third-party debt. The transaction is anticipated to close by the end of 2024, pending regulatory clearances and shareholder approval from Tianjin Pharmaceutical Da Ren Tang Group Corp.
Upon the transaction’s completion, Haleon and DRTG have agreed that Haleon will have an option to acquire the remaining 12% shareholding in TSKF, giving the company an opportunity to take full control of the joint venture in the future.
advil $637m investment : Haleon’s Growth Trajectory Since Formation
Haleon was created through the consolidation of the consumer health businesses of GSK, Novartis, and Pfizer, before being listed as an independent company on the London and New York stock exchanges in July 2022. The company boasts an extensive portfolio of well-established brands, including Sensodyne and Aquafresh toothpastes, Advil, Tums, and Centrum multivitamins.
This Advil $637M investment marks a major milestone for Haleon as it deepens its involvement in China, which has proven to be a fertile ground for consumer health growth. TSKF’s production of gel pain relievers, like Advil, fits well with Haleon’s expanding product line in China, further enhancing the company’s market presence.
Continued Investment in China’s Healthcare Market
Haleon’s expansion is also strategically aligned with the growth trends in China’s healthcare sector. With rising consumer demand for quality healthcare products and pain relief solutions, the Advil $637M investment is positioned to leverage these trends to accelerate Haleon’s market share growth.
